MiR-590 suppresses the progression of non-small cell lung cancer by regulating YAP1 and Wnt/B-catenin signaling
Clin. transl. oncol. (Print)
; 24(3): 546-555, marzo 2022.
Artigo
em Inglês
| IBECS
| ID: ibc-203549
Biblioteca responsável:
ES1.1
Localização: ES15.1 - BNCS
ABSTRACT
ObjectiveAccumulating evidence has been revealed that miR-590 is involved in the progression and carcinogenesis of various cancers. However, the molecular mechanism of miR-590 in non-small-cell lung cancer (NSCLC) remains unclear.MethodsQuantitative reverse transcription-PCR (qRT-PCR), western blot, MTT, and transwell assay were applied to investigate the functional role of miR-590 in this study. Dual luciferase reporter assay was utilized to investigate the interaction between YAP1 and miR-590 expression. Cells transfected with miR-590 mimic or inhibitor were subjected to western blot to investigate the role of Wnt/β-catenin signaling in NSCLC modulated by miR-590.ResultsMiR-590 was down-regulated in NSCLC tissues and cells. KaplanMeier analysis found that the higher expression of miR-590 in NSCLC patients, the more improved survival rate of NSCLC patients. Over-expression of miR-590 inhibited NSCLC cell proliferation, migration, and invasion. Moreover, increasing miR-590 suppressed Yes-associated protein 1 (YAP1) expression and inhibited the Wnt/β-catenin pathway in NSCLC cells. Furthermore, miR-590 was negatively correlated with YAP1 expression.ConclusionThese findings demonstrated that the miR-590/YAP1 axis exerted an important role in the progression of NSCLC, suggesting that miR-590 might be the appealing prognostic marker for NSCLC treatment.
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Carcinoma Pulmonar de Células não Pequenas
/
Proteínas RGS
/
MicroRNAs
/
Neoplasias Pulmonares
Limite:
Humanos
Idioma:
Inglês
Revista:
Clin. transl. oncol. (Print)
Ano de publicação:
2022
Tipo de documento:
Artigo
Instituição/País de afiliação:
Bejing Chaoyang District Sanhuan Cancer Hospital/China
/
National Clinical Research Center for Cancer